Hebei Changshan Biochemical Pharmaceutical (300255.SZ): The clinical trial application for Abbinaide peptide injection for weight loss indication has been approved.
Changshan Pharmaceutical (300255.SZ) announced that the company and its holding subsidiary Changshan Kaijie Health Biopharmaceutical Research and Development (Hebei)...
Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that the company and its holding subsidiary, Changshan Kaijie Jian Biological Pharmaceutical Research and Development (Hebei) Co., Ltd. (referred to as "Changshan Kaijie Jian"), recently received the Drug Clinical Trial Approval Letter issued by the National Medical Products Administration (NMPA). The joint application for clinical trials of Buepronatide injection for weight loss indication has been approved.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
